Does creatine help prevent muscle loss with GLP-1 medications like Ozempic?
Whether creatine genuinely helps preserve muscle during GLP-1 medication use is unknown, because it has never been directly studied. Resistance training and adequate protein intake remain the only approach with any supporting evidence.
Up to 40% of the weight you lose with GLP-1 medications like semaglutide can come from lean mass. That includes not just muscle tissue, but also water and organ tissue. Even so, this is a genuine concern: people who lose a relatively large amount of muscle mass may end up with a slower metabolism and less strength in the long run.
Creatine is sometimes mentioned in that context as a supplement to protect muscle. But to be honest, there is no direct evidence at all for this combination. Not a single study has been done in people taking GLP-1 medications who also took creatine. The reasoning is based on what creatine does in other situations, not on research in this specific group.
In another context of involuntary muscle loss, namely hormone therapy for prostate cancer, a systematic review of several small studies did find a trend toward greater muscle mass with creatine supplementation. However, that trend was not statistically significant. In other words: a cautiously positive signal, but no firm conclusion.
Resistance training and adequate protein intake are recommended as the first and best measure when using GLP-1 medications. Here too, the evidence specifically in combination with these medications is limited and mixed, but the general support for both is much stronger than for creatine. If you are considering creatine, treat it as an addition to, not a replacement for, exercise and sufficient protein.
All claims are drawn from two sources: PMID 40401903 (on GLP-1 medications and lean mass, including the recommendation of creatine as a theoretical option) and PMID 41703670 (systematic review of RCTs in hormone therapy for prostate cancer). There are no studies in GLP-1 users that have examined creatine.